Source: earnings_events
Changes History →Track the stock moves that actually matter.
BestStocks detects meaningful changes across price, volume, earnings, filings, valuation, analyst revisions, and risk signals — and shows you the evidence behind each one.
Investment research built around change detection.
BestStocks identifies what changed across companies and sectors, explains why it matters, and helps investors spot opportunities worth investigating.
What changed: Construction Partners, Inc. (ROAD) reported EPS of $1.00 vs. consensus estimate of $1.08 for Q4 FY2026, missing by 7.4%.
Source: earnings_events
Changes History →Watch for ROAD's next earnings announcement (scheduled 2026-11-24, date not yet confirmed) to assess whether Q4's miss represents a one-off or a deteriorating earnings trajectory.
Twilio extended a weeks-long pullback, declining 5.83% to $184.51 as lingering concerns over slowing revenue growth persist following late-October earnings (web_catalyst). Q3 beat headline numbers but Q4 guidance of 11–12% organic growth fell short of Q3's ~16%, triggering sustained selling pressure since late October despite positive announcements today, including a Chelsea FC case study. Volume of 1.17M shares traded 59% below average for this point in the session, suggesting limited conviction in either direction.
Twilio fell 3.33% to $189.41 despite announcing a new customer win with Chelsea FC, highlighted in a Business Wire release today showing the platform reduced campaign launch times from 48 hours to under 15 minutes. Volume traded 650,759 shares by the 210-minute mark, tracking at 0.47x the historical average for this time of day — below normal levels.
Twilio earnings on February 11, 2027 (consensus EPS estimate $1.53); any updates on AI product scaling and Q1 2027 guidance will be critical to reversing the negative momentum.
Nike stock fell 5.18% to $34.43 following its Investor Day presentation, which revealed an extended turnaround timeline under its "Full Stride Ahead" strategy—projecting revenue declines through 2028 before a $5 billion rebound target by 2031 (defenseworld.net). The selloff reflects investor disappointment over the prolonged contraction period and was compounded by Fisher Asset Management trimming its holdings and analyst warnings of ongoing fundamental weakness amid broader retail headwinds. Volume ran at 1.07x the time-adjusted average, indicating normal participation.
Nike faces revenue headwinds through 2028 before a targeted $5 billion rebound by 2031, according to defenseworld.net reporting on the company's forward guidance. Simultaneously, Fisher Asset Management trimmed its holdings in NKE. The stock fell 3.55% to $35.02 on above-average volume (1.62x normal for this time of day), reflecting investor concern over the near-term contraction.
NKE earnings on 2026-12-17 (consensus EPS estimate $0.38); any updates on "Full Stride Ahead" execution metrics and fiscal 2027 guidance confirmation.
What changed: AMD fell 8.18% to $486.76 after high-profile investor David Tepper exited his AMD position and opened a $172M Oracle stake instead, per 247wallst.com. The move reverses earlier premarket gains tied to OpenAI's report that its AI improved AMD's best chip design by up to 14%. Volume surged to 26.0M shares (3.24x expected at this point in the session), signaling elevated institutional activity.
Detected Nov 19, 3:30 PM ET
Changes History →AMD earnings on 2027-02-02 (consensus EPS $2.90) and any update on AI chip adoption or design wins in coming weeks.
What changed: Booking Holdings shares fell 3.51% to $147.90 on softer travel demand expectations and macroeconomic pressures. Per WSJ reporting cited by Google's AI Overview, management guided for slower Q4 2026 room-night growth of 1–3% (down from 7% in Q3), citing geopolitical conflicts and tough year-over-year comparisons. Volume of 4.3M shares traded at 0.62x the expected level for this point in the session, below average.
Detected Nov 19, 3:30 PM ET
Changes History →Q4 2026 earnings (scheduled for February 17, 2027; consensus EPS estimate $2.19) and any management commentary on Q1 2027 bookings trends and the impact of geopolitical disruptions on demand.
What changed: Centene shares fell 2.87% to $65.52, extending a two-day selloff triggered by proposed CMS rules targeting increased insurer audits and Medicare Advantage overpayment recovery across managed care plans (reported via finance.yahoo.com). The decline reflects sector-wide pressure on managed care insurers rather than a company-specific event; volume remains below average at 0.57x the historical rate for this time of session.
Detected Nov 19, 3:30 PM ET
Changes History →Centene's Q4 2026 earnings (scheduled for February 5, 2027) will be critical to assess the financial impact of CMS audit intensity and any guidance revisions for 2027 related to overpayment exposure.
What changed: Oracle shares fell 2.15% to $111.44 intraday as the company faces mounting pressure from heavy AI infrastructure spending ($28.5B capex last quarter, -$5.4B free cash flow) and customer concentration risks, per web reports citing $300B in RPO tied to OpenAI. Microsoft's wind-down of an AI capacity rental arrangement with Oracle and reports of canceled AI chip leases compound concerns. Volume traded 0.63x expected pace at this time of day.
Detected Nov 19, 3:30 PM ET
Changes History →Oracle earnings on December 9, 2026 (consensus EPS estimate $1.88); guidance on capex plans and OpenAI partnership status.
What changed: Salesforce shares fell 2.26% to $186.09, driven by fresh layoff reports announced November 18 combined with broader AI disruption concerns weighing on software stocks ahead of Q3 earnings (per web_catalyst synthesis and Yahoo Finance reporting). Volume of 3.6M shares runs at 0.82x expected for this point in the session—within normal range.
Detected Nov 19, 3:30 PM ET
Changes History →Q3 earnings report scheduled for December 2, 2026, and management commentary on job-cut rationale, AI product adoption, and full-year guidance.
What changed: Intuitive Surgical shares fell 2.15% to $411.90 on technical selling after breaking below the 200-day moving average, according to defenseworld.net. Investor caution persists around instrument pricing pressure in China (projected 3–5% revenue-per-procedure headwinds once implemented) and elevated valuation near 50x P/E despite strong Q3 results (22% revenue growth), per the web catalyst. Volume remained subdued at 0.52x expected for this stage of session.
Detected Nov 19, 3:30 PM ET
Changes History →ISRG earnings on 2027-01-28 (consensus EPS $2.96); monitor for any announcements on China pricing phase-in timeline or da Vinci system placement updates.
What changed: Caterpillar fell 2.82% to $543.01 as part of a broader pullback in AI-linked infrastructure trades. The decline reflects investor concerns over the durability of data-center spending that had driven the stock higher earlier in 2026, combined with management's guidance for only modest Q4 sales growth and softer construction equipment volumes (per web sources including Zacks and Motley Fool coverage). Volume of 1.39M shares is tracking at 0.96x normal for this time of session.
Detected Nov 19, 3:30 PM ET
Changes History →Caterpillar earnings scheduled for 2027-02-04 (consensus EPS estimate $6.47); also monitor for updates on Q4 sales trajectory and any commentary on data-center turbine/engine demand sustainability.
NVIDIA fell 2.65% to $146.96 as leadership uncertainty and regulatory headwinds overshadowed better-than-expected Q3 earnings. The stock has retraced gains following CEO Jensen Huang's resignation and board criticism from figures including Elon Musk (247wallst.com), amid investor concerns about the company's direction and ongoing export-control scrutiny on AI chip access to China. Volume at 237M shares is running 1.22x expected for this point in the session.
NVIDIA rose 1.60% to $153.37 as elevated volume (2.55x expected at this hour) accompanied intraday buying, despite negative headlines regarding board actions and employee retention concerns. 247wallst.com reported Elon Musk criticized the board's handling of leadership, while separately NVIDIA is accelerating pay raises to retain staff following recent executive transitions.
Permanent CEO appointment announcement (no timeline confirmed); earnings on Feb. 24, 2027 (consensus $2.88 EPS); Commerce Department export-control rule enforcement and updates.
Latest research
View all research →In-depth equity research from the BestStocks desk — earnings breakdowns, valuation deep dives, and sector analysis behind the changes we detect.

Target (TGT) Jumps Toward a 52-Week High on a Traffic-Led Q3 Beat and a Raised Sales Outlook
Target (TGT) jumped more than 5% on November 18, pushing toward its 52-week high after a traffic-led fiscal third-quarter beat — a gain that substantially outpaced flat big-box peers and the broad market. EPS of $2.65 (GAAP and adjusted alike) cleared the ~$2.07 expected, but about $0.50 came from a one-time $301 million tariff refund, leaving underlying EPS near $2.15 (still up ~21% year over year). What mattered more was the mix: comparable sales rose 5.6%, driven by a 5.0% gain in traffic — more shoppers, the proof point for a company whose slump was a traffic problem — though the category recovery stayed uneven, with apparel and home soft. Target also raised its full-year sales-growth outlook to around 6%. The catch is price: after more than doubling off an $83 low, the stock sits near its 52-week high and above the analysts' average target of ~$165.56, with only a Hold consensus, so much of the initial re-rating may already be reflected and the holiday quarter now has to confirm the recovery.

Disney (DIS) Nears a 52-Week High on a Q4 Beat, a 33% Dividend Hike, and a $3 Billion Savings Target
The Walt Disney Company rose about 2.5% to roughly $122 — within about 1% of a 52-week high — on November 17 after reporting fiscal fourth-quarter results, outperforming flat media peers and the broader market. Revenue rose 16% to $25.9 billion (though an extra 53rd week flatters that to roughly 8% underlying) and adjusted EPS of $1.77 beat expectations, with the standout being streaming: operating income more than doubled to $824 million (about +65% excluding the extra week), confirming the direct-to-consumer business is becoming meaningfully profitable. Management paired the beat with a shareholder-friendly message — a 33% dividend increase (to $2.00 a year) and a target of about $3 billion in annual cost savings by fiscal 2029 — while reaffirming double-digit adjusted-EPS growth in fiscal 2027 and, notably, raising content spending ~9% to roughly $26 billion, so this is still a growth-and-invest story. The turnaround, initiated under Bob Iger and now led by CEO Josh D'Amaro, is clearly working — but the catch is price: the stock has risen ~14% in a year to near its 52-week high, with only ~5% upside to the average analyst target, so much of it is already in the shares.

DoorDash's $17 Billion Instacart Takeover Heads to a DOJ Antitrust Review
DoorDash's roughly $17 billion, $65-a-share acquisition of Instacart now heads to a U.S. Department of Justice antitrust review, Reuters and Bloomberg reported — the DOJ, not the FTC, taking the lead on a deal to combine the top restaurant-delivery and online-grocery platforms. A review is not a challenge, and both companies still target a late-2027/early-2028 close, but with CART near $59 versus the $65 offer, the ~11% spread tells the real story: time, regulatory risk, and a stock-heavy slice of the consideration that floats with a falling DoorDash.

Summit Therapeutics (SMMT) Plunges ~16% to a 52-Week Low After the FDA Rejects Ivonescimab's First US Filing
Summit Therapeutics plunged about 16% to roughly $11.82 — a fresh 52-week low — on November 16 after disclosing that the FDA had issued a Complete Response Letter (a rejection, for now) for its lead drug, ivonescimab. The move was emphatically company-specific: on a day the broad market and biotech indexes each fell about 2%, Summit dropped eight times as hard. The CRL covers ivonescimab plus chemotherapy after EGFR-targeted treatment in non-small cell lung cancer, from the Phase 3 HARMONi trial — which clearly met its progression-free survival goal (6.8 vs 4.4 months) but whose primary overall-survival analysis narrowly missed significance (16.8 vs 14.0 months, HR 0.79, p=0.057), and the FDA judged the benefit-risk insufficient. Crucially, this is not a verdict that the drug fails to extend life: in a separate first-line trial (China's HARMONi-2) ivonescimab beat Keytruda on overall survival (30.8 vs 22.6 months, HR 0.73, p=0.009). Several things keep the CRL from being thesis-ending: it covers one smaller indication; the far larger global first-line opportunity (HARMONi-3, HARMONi-7) is still ahead; and just six weeks earlier AstraZeneca completed a $2 billion strategic investment in Summit. Even after the drop, Summit is a ~$9.4 billion company with roughly $2.6 billion of liquidity (including the AstraZeneca cash) and ~27%-of-float short interest — a well-funded, AstraZeneca-backed, polarizing bet whose value rests almost entirely on first-line survival data still to come.

Tyson Foods (TSN) Jumps ~7% on a Better-Than-Feared Q4 and an Outlook for Sharply Narrower Beef Losses
Tyson Foods jumped about 7% to roughly $62.80 on November 16 after reporting fiscal fourth-quarter results — and it did so on a risk-off day, with the S&P 500 down nearly 2% as the AI, chip and crypto trades sold off. For a defensive consumer-staples name to rise ~7% while the market fell is a clear company-specific signal, reinforced by a rotation into cheap, low-beta stocks. Tyson's adjusted EPS of $0.61 was roughly in line with or slightly above commonly cited consensus estimates, but it was down ~47% year over year, and on a GAAP basis the company posted a $0.22-per-share loss; revenue of $14.6 billion beat but underlying sales fell ~4%, and adjusted operating income dropped 41%. What drove the jump was the outlook — specifically for beef: management guided its Beef segment from a $654 million fiscal-2026 loss toward roughly breakeven in 2027 (a $300 million loss to a $100 million profit), a sharp narrowing of the biggest drag on earnings caused by a historic cattle shortage, even though total-company adjusted operating-income guidance ($1.7–$2.15 billion) is roughly flat versus this year's $1.977 billion. The stock looks cheap on sales (~0.4x) and reasonable on forward earnings (~16x), but after the pop it sits right at the analysts' average target with a Hold rating — so the move reads as a weak-but-better-than-feared quarter plus a credible beef-loss turn, re-rating a beaten-down defensive in one session.

Black Hills and NorthWestern Complete Their Merger to Form Bright Horizon Energy (NYSE: HZN)
Black Hills and NorthWestern Energy completed an all-stock merger of equals on November 13, 2026, forming Bright Horizon Energy (NYSE: HZN) — a roughly $12 billion regulated utility serving about 2.2 million electric and gas customers across eight states, with a growing pipeline of data-center electricity demand.











